FDA Rejects Disc Medicine Drug

On February 13, 2026, the United States — Food and Drug Administration>>> issued a Complete Response Letter to Disc Medicine>>> regarding its bitopertin program, stating that the new drug application could not be approved due to uncertainties requiring additional evidence. Following this news, Disc Medicine>>>'s stock price experienced a sharp decline of 22%. In response, Rosen Law Firm>>>, a global investor rights law firm, initiated an investigation into potential securities claims against Disc Medicine>>>. The firm is preparing a class action lawsuit to recover investor losses, alleging that Disc Medicine>>> may have issued materially misleading business information to the investing public. Philip Kim>>> and Lawrence Rosen>>> of Rosen Law Firm>>> are leading the efforts to gather affected investors.